by Chugai Pharmaceutical has signed a joint research and license agreement with GERO in Singapore-based biotechnology company GERO to create new antibody candidates for age-related disorders.
Their cooperation will use Chugai antibody technology to develop new treatments for goals that have been identified by GERO’s AI platform, which analyzes human data sets.
Chugai gets exclusive worldwide rights to research, develop, produce and commercialize antibodies for these goals.
Gero CEO Peter Fedichev stated: “Our AI platform was built to identify therapeutic goals that stimulate and possibly age several age-related diseases.
“In this collaboration we want to translate those insights into therapeutic that can help restore the lost function. This collaboration with Chugai is an important step in the direction of achieving Gero’s mission: to use the biological processes of becoming human parent.”
The financial conditions include a first payment from Chugai to GERO, with the potential for extra payments up to $ 250 million, depending on the achievement of specific development or sales mile poles.
If Chugai successfully launches a product, it will also pay Gero Royalties about sales.
Chugai president and CEO Dr. Osamu Okuda stated: “We believe that open innovation with external partners, including leading global players, is extremely important for achieving the global first -class drug discovery in our growth strategy by 2030, Top I 2030.
“By combining Gero’s Target Discovery technology with Chugai’s Drug Discovery Technologies, we will speed up the establishment of innovation.”
Gero was represented by Ropes & Gray, with a team led by Life Sciences Licensing Partner Hannah England and Associate Ian Nilsen, together with IP transaction adviser Ryan Murphey and Life Sciences Licensing Associates Mallory Ursul and Ben Ellington.
In January 2025, Chugai and Araris Biotech formed a research cooperation and option-to-license agreement aimed at conjugates with antibody medicines, appreciated up to $ 780 million.
“Chugai and Gero Link about antibody drugs for age -related disorders” was originally made and published by Pharmaceutical Technology, a Global Data brand.
The information on this site is only included for general informative purposes. It is not intended to be an intended for advice on which you must trust, and we do not give a representation, warranty or warranty, whether we express whether we are implicit with regard to its accuracy or completeness. You must obtain professional or specialist advice before taking or taking all promotion on our site on the basis of the content.
